These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25678187)

  • 41. [Chemotherapy of renal cell carcinoma: experimental study and clinical effect].
    Kanda H; Matsuura T; Akiyama T; Kurita T
    Hinyokika Kiyo; 1988 Nov; 34(11):1879-84. PubMed ID: 3242362
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted therapies: another option for metastatic RCC.
    Hutchinson L
    Nat Rev Clin Oncol; 2013 Nov; 10(11):607. PubMed ID: 24061041
    [No Abstract]   [Full Text] [Related]  

  • 43. Predictors of response to targeted therapy in renal cell carcinoma.
    Eisengart LJ; MacVicar GR; Yang XJ
    Arch Pathol Lab Med; 2012 May; 136(5):490-5. PubMed ID: 22229848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications.
    Pantuck AJ; Thomas G; Belldegrun AS; Figlin RA
    Semin Oncol; 2006 Oct; 33(5):607-13. PubMed ID: 17045090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Understanding the importance of smart drugs in renal cell carcinoma.
    Patard JJ; Rioux-Leclercq N; Fergelot P
    Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Signal-transduction inhibitors in renal cell carcinoma.
    Vogelzang NJ; Sternberg CN
    BJU Int; 2007 May; 99(5 Pt B):1289-95. PubMed ID: 17441926
    [No Abstract]   [Full Text] [Related]  

  • 47. Emerging drugs for renal cell carcinoma.
    Shaheen PE; Bukowski RM
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):773-95. PubMed ID: 16262562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel challenges associated with novel agents: the evolving scenario in renal cell carcinoma.
    Di Lorenzo G; Buonerba C
    Future Oncol; 2016 Feb; 12(3):277-9. PubMed ID: 26768297
    [No Abstract]   [Full Text] [Related]  

  • 49. Interleukin-6 as an emerging regulator of renal cell cancer.
    Kamińska K; Czarnecka AM; Escudier B; Lian F; Szczylik C
    Urol Oncol; 2015 Nov; 33(11):476-85. PubMed ID: 26296264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sequential use of targeted agents in the treatment of renal cell carcinoma.
    Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted agents for the treatment of advanced renal cell carcinoma.
    Stadler WM
    Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fibroblast growth factor-1 transcriptionally induces membrane type-1 matrix metalloproteinase expression in prostate carcinoma cell line.
    Udayakumar TS; Nagle RB; Bowden GT
    Prostate; 2004 Jan; 58(1):66-75. PubMed ID: 14673954
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NCAM and FGFR1 coexpression and colocalization in renal tumors.
    Ćirović S; Vještica J; Mueller CA; Tatić S; Vasiljević J; Milenković S; Mueller GA; Marković-Lipkovski J
    Int J Clin Exp Pathol; 2014; 7(4):1402-14. PubMed ID: 24817936
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FGFR-targeted therapeutics for the treatment of breast cancer.
    De Luca A; Frezzetti D; Gallo M; Normanno N
    Expert Opin Investig Drugs; 2017 Mar; 26(3):303-311. PubMed ID: 28121208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FGFR Signaling as a Target for Lung Cancer Therapy.
    Desai A; Adjei AA
    J Thorac Oncol; 2016 Jan; 11(1):9-20. PubMed ID: 26762735
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive Biomarkers for Molecularly Targeted Therapies in Renal Cell Carcinoma.
    Brugarolas J
    J Natl Compr Canc Netw; 2016 Jul; 14(7):925-7. PubMed ID: 27407131
    [No Abstract]   [Full Text] [Related]  

  • 57. Discovery of a novel target for renal cell carcinoma: transglutaminase 2.
    Kang JH; Lee SH; Kim SY
    Cell Death Dis; 2016 Apr; 7(4):e2200. PubMed ID: 27100894
    [No Abstract]   [Full Text] [Related]  

  • 58. Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy.
    Piva F; Giulietti M; Santoni M; Occhipinti G; Scarpelli M; Lopez-Beltran A; Cheng L; Principato G; Montironi R
    Mol Diagn Ther; 2016 Apr; 20(2):111-7. PubMed ID: 26940073
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma.
    Fujimoto K; Ichimori Y; Yamaguchi H; Arai K; Futami T; Ozono S; Hirao Y; Kakizoe T; Terada M; Okajima E
    Jpn J Cancer Res; 1995 Feb; 86(2):182-6. PubMed ID: 7730142
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Renal cell carcinomas. Pathomorphologic diagnosis in the light of modern pharmacotherapy].
    Störkel S
    Pathologe; 2010 Feb; 31(1):50-3. PubMed ID: 20084384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.